TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05571059: Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Sponsor: Cumberland Pharmaceuticals · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 128 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,449,500

Rescue Site Savings

+$1,621,500

Unlock Full NCT05571059 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05571059 Rescue Dossier →